Alembic Pharmaceuticals informs about media release
Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Methotrexate Injection USP, 50 mg/2 mL (25 mg/mL) Multi-Dose Vials & 1g/40 mL (25 mg/mL) Single-Dose Vials.
The above information is a part of company’s filings submitted to BSE.
